[go: up one dir, main page]

IL132896A0 - Cachexia remedy - Google Patents

Cachexia remedy

Info

Publication number
IL132896A0
IL132896A0 IL13289698A IL13289698A IL132896A0 IL 132896 A0 IL132896 A0 IL 132896A0 IL 13289698 A IL13289698 A IL 13289698A IL 13289698 A IL13289698 A IL 13289698A IL 132896 A0 IL132896 A0 IL 132896A0
Authority
IL
Israel
Prior art keywords
cachexia
parathyroid hormone
related peptide
remedy
inhibiting
Prior art date
Application number
IL13289698A
Other languages
English (en)
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL132896A0 publication Critical patent/IL132896A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Valve Device For Special Equipments (AREA)
  • Confectionery (AREA)
  • Massaging Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polymerisation Methods In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13289698A 1997-05-15 1998-05-13 Cachexia remedy IL132896A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12550597 1997-05-15
JP19444597 1997-07-18
PCT/JP1998/002116 WO1998051329A1 (fr) 1997-05-15 1998-05-13 Remede contre la cachexie

Publications (1)

Publication Number Publication Date
IL132896A0 true IL132896A0 (en) 2001-03-19

Family

ID=26461935

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13289698A IL132896A0 (en) 1997-05-15 1998-05-13 Cachexia remedy

Country Status (19)

Country Link
US (2) US20020165363A1 (pl)
EP (1) EP1004313B1 (pl)
KR (1) KR100508338B1 (pl)
CN (1) CN1329080C (pl)
AT (1) ATE361099T1 (pl)
AU (1) AU750021C (pl)
BR (1) BR9809629A (pl)
CA (1) CA2289910A1 (pl)
DE (1) DE69837707T2 (pl)
ES (1) ES2285769T3 (pl)
HK (1) HK1029047A1 (pl)
IL (1) IL132896A0 (pl)
NO (1) NO995558L (pl)
PL (1) PL193575B1 (pl)
SK (1) SK155799A3 (pl)
TR (1) TR199902800T2 (pl)
TW (1) TWI227140B (pl)
UA (1) UA74130C2 (pl)
WO (1) WO1998051329A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1329080C (zh) 1997-05-15 2007-08-01 中外制药株式会社 恶病质的治疗剂
WO2001002011A1 (fr) * 1999-07-02 2001-01-11 Chugai Seiyaku Kabushiki Kaisha REMEDES CONTRE LES MALADIES CAUSEES PAR PTH OU PTHrP
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
EP1987842A1 (en) 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitor
EP1312378A4 (en) * 2000-08-16 2004-03-17 Chugai Pharmaceutical Co Ltd AGENTS FOR THE RELIEF OF SYMPTOMS CAUSED BY JOINT DISEASES
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
SG183742A1 (en) 2007-05-21 2012-09-27 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8257684B2 (en) * 2008-03-26 2012-09-04 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
WO2011066369A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
JP5929753B2 (ja) 2011-01-31 2016-06-08 東レ株式会社 悪液質の治療又は予防剤
EP2875824B1 (en) 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Composition for preventing or treating cachexia
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー,リミティド ホルモン分泌調節剤、及びそれを含む組成物
BR112016008331B1 (pt) 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー,リミティド 前立腺癌治療用組成物
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2886946T3 (es) 2015-07-02 2021-12-21 Gemvax & Kael Co Ltd Péptido con efecto antiviral y composición que lo contiene
CN117018162A (zh) 2016-04-07 2023-11-10 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293130A3 (en) * 1987-05-26 1990-06-13 Merck & Co. Inc. Dimers of parathyroid hormone antagonists
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
US5001223A (en) 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
EP0417191B1 (en) 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5217896A (en) * 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
JPH02207099A (ja) 1989-02-07 1990-08-16 Tonen Corp PTHrP関連ペプチド、その製造法及び用途
CA2035179C (en) 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
CA2087190A1 (en) * 1990-07-13 1992-01-14 Fred E. Cohen Parathyroid hormone analogues modified at positions
WO1992017602A1 (en) 1991-04-05 1992-10-15 The General Hospital Corporation Office Of Technology Affairs Parathyroid hormone receptor and dna encoding same
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
ES2179824T3 (es) 1991-12-20 2003-02-01 Yamanouchi Pharma Co Ltd Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3504697B2 (ja) 1993-09-30 2004-03-08 株式会社先端生命科学研究所 PTHrPアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
JPH07316195A (ja) 1994-05-25 1995-12-05 Nippon Kayaku Co Ltd 新規なPTHrP関連ペプチド及びその用途
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5626845A (en) * 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis
EP0813423B1 (en) * 1995-01-23 2002-07-03 Xenotech Incorporated Composition to inhibit osteolysis and metastasis
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
DE69637104T2 (de) 1995-02-20 2008-01-31 Yukio Kato Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
DE69610826T2 (de) 1995-03-01 2001-05-03 Stryker Corp., Kalamazoo Morphogeninduzierte regenerierung der dentin
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US5660826A (en) 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP
ATE219374T1 (de) 1996-02-01 2002-07-15 Chugai Pharmaceutical Co Ltd Medikamente für die behandlung oder vorbeugung von thrombocytopenie
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
CN1329080C (zh) 1997-05-15 2007-08-01 中外制药株式会社 恶病质的治疗剂
JP4372240B2 (ja) 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
JP4414494B2 (ja) 1998-02-03 2010-02-10 旭化成ファーマ株式会社 白血球減少症の予防剤および治療剤
WO1999057139A2 (en) 1998-05-05 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Pth2 receptor selective compounds
JP2000080100A (ja) 1998-06-17 2000-03-21 Japan Tobacco Inc 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
TWI234464B (en) 1998-06-26 2005-06-21 Chugai Pharmaceutical Co Ltd Medicine constituents for hypercalcemic crisis

Also Published As

Publication number Publication date
ES2285769T3 (es) 2007-11-16
DE69837707T2 (de) 2008-01-10
KR20010012613A (ko) 2001-02-15
AU750021B2 (en) 2002-07-11
AU750021C (en) 2003-10-16
CN1255858A (zh) 2000-06-07
UA74130C2 (uk) 2005-11-15
ATE361099T1 (de) 2007-05-15
TR199902800T2 (xx) 2000-04-21
US7468184B2 (en) 2008-12-23
PL193575B1 (pl) 2007-02-28
CN1329080C (zh) 2007-08-01
BR9809629A (pt) 2000-07-04
EP1004313B1 (en) 2007-05-02
PL336797A1 (en) 2000-07-17
NO995558D0 (no) 1999-11-12
KR100508338B1 (ko) 2005-08-17
EP1004313A1 (en) 2000-05-31
AU7236998A (en) 1998-12-08
SK155799A3 (en) 2000-06-12
US20020165363A1 (en) 2002-11-07
TWI227140B (en) 2005-02-01
CA2289910A1 (en) 1998-11-19
NO995558L (no) 2000-01-12
DE69837707D1 (de) 2007-06-14
EP1004313A4 (en) 2005-01-19
HK1029047A1 (en) 2001-03-23
US20030138424A1 (en) 2003-07-24
WO1998051329A1 (fr) 1998-11-19

Similar Documents

Publication Publication Date Title
HK1029047A1 (en) Cachexia remedy
AU5732101A (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1047425A4 (en) INTEGRIN RECEPTOR ANTAGONISTS
ITRM940805A0 (it) Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
TR199801594A3 (tr) CCR-3 reseptör antagonistleri.
HUP0101411A3 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
AU2002366384A8 (en) Insulin and igf-1 receptor agonists and antagonists
ZA9610535B (en) Antagonists of gonadotropin releasing hormone.
ZA964383B (en) Hepatocyte growth factor receptor antagonists and uses thereof.
HK1029574A1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
EP1007051A4 (en) INTEGRIN RECEPTOR ANTAGONISTS
HK1033313A1 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists.
TR200003768T2 (tr) Hiperkalsemik krizler için terapötik aktif madde.
EP1029916A4 (en) HUMAN LYSOPHOSPHATIDE ACID RECEPTOR AND USE OF SAID RECEPTOR
EP1567178A4 (en) MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS
EP1027337A4 (en) Integrin receptor Antagonist
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
AU6596096A (en) Calcitonin gene-related peptide receptor component factor (houdc44)
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
GB9928805D0 (en) Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
WO2001027146A3 (en) Chemokine receptor
WO2001094415A3 (en) Nuclear hormone receptor
ZA200208518B (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein.
ZA982603B (en) NK-1 receptor antagonists for the treatment of delayed emesis.
ES1038384Y (es) Dispositivo vibrador para arboles.